Most Hungarians expect more subsidization and better access to innovative meds

According to the Association of Innovative Pharmaceutical Manufacturers (AIPM), to ensure that Hungarian patients can access the newest medicinal products, the level of public spending on medicines should be raised at least to the average of the Visegrad countries.

The AIPM’s country-wide study shows that Hungarians believe the state should subsidize the price of newly-developed medicines to a greater extent and make them accessible to patients faster, and to do so, it should decide much more frequently than so far on the social security subsidy for these modern medicinal products.

The study found that most Hungarians (92%) are aware that the state provides subsidy for prescription-only and hospital medicines. Most (52%) also believe that more expensive medicinal products should be given more subsidy. 64% of the respondents believe that the state should clearly subsidize medicines that are more expensive than 1,000 forints ($3.61), while 31% say this should be the case with medicines that cost more than 5,000 forints. Most people believe the state should subsidize the price of newly-developed medicines to a greater extent and make them accessible to patients faster.